Fluphenazine pharmacokinetics and therapeutic response.
We conducted a double-blind study of therapeutic outcome versus mean steady-state levels in 29 newly admitted schizophrenic and schizoaffective patients who were treated with a constant dose of fluphenazine HCI over a 2-week period. both an upper and lower end of the therapeutic window were suggested by three nonresponders whose plasma levels were above 2.8 ng per ml and by two nonresponders and one partial responder whose plasma levels were below 0.2 ng per ml. The mean terminal half-life of fluphenazine (+ or - SD) was 16.4 + or - 13.3 h. We found that concomitant use of benztropn mesylate during the initial 4 weeks of fluphenazine treatment did not significantly alter fluphenazine plasma levels.
D000107:Acetylation; D000328:Adult; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D005260:Female; D005476:Fluphenazine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D007700:Kinetics; D008297:Male; D012559:Schizophrenia / Q000188:drug therapy*; D013997:Time Factors
D005476:Fluphenazine